6505--Allopurinol Tablets
ID: 36E79725R0067Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/workspace/contract/opp/9a00d4d79ab940229b472c5993c5d7b3/view
Timeline
    Description

    The Department of Veterans Affairs is seeking proposals for the procurement of Allopurinol Tablets (100mg and 300mg in various bottle sizes) to be distributed through the VA and DoD Pharmaceutical Prime Vendor Programs. Offerors are required to provide pricing for all line items and option years, including a 0.5% Cost Recovery Fee, and must submit unique 11-digit National Drug Codes (NDCs) for each product. This procurement is crucial for ensuring the availability of essential medications for veterans and active-duty military personnel. The solicitation has been amended to extend the deadline for offers to December 2, 2025, at 2:30 PM CST, and interested parties should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further information.

    Point(s) of Contact
    Matthew S PoulinContract Specialist
    Matthew.Poulin@va.gov
    Files
    Title
    Posted
    36E79725R0067 0001.docx
    The Department of Veterans Affairs has issued Amendment 0001 to Solicitation 36E79725R0067, extending the deadline for offers. The original closing date of November 24, 2025, has been extended to December 2, 2025, at 2:30 PM CST. This amendment, dated November 21, 2025, was issued by the Department of Veterans Affairs, OPAL / National Acquisition Center in Hines, IL. All other terms and conditions of the solicitation remain unchanged. Offerors must acknowledge receipt of this amendment to ensure their offer is considered.
    36E79725R0067_1.docx
    The Department of Veterans Affairs (VA) National Acquisition Center issued Presolicitation Notice 36E79725R0067 for an unrestricted Request for Proposal (RFP) to procure Allopurinol Tablets. This contract aims to secure an uninterrupted supply of Allopurinol 100MG and 300MG tablets for the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The contract will span one year with four one-year option periods, distributing items via VA and DoD Pharmaceutical Prime Vendor Programs. Offerors must provide drugs with unique NDC numbers and labels. The solicitation, with NAICS code 325412, will be issued electronically around October 16, 2025, with a tentative closing date of October 30, 2025. Interested parties should monitor sam.gov for updates, and inquiries can be directed to Matthew Poulin at Matthew.Poulin@va.gov.
    36E79725R0067.docx
    This government solicitation, 36E79725R0067, from the Department of Veterans Affairs, outlines a Request for Proposal (RFP) for Allopurinol Tablets (100mg and 300mg in various bottle sizes) to be distributed through VA and DoD Pharmaceutical Prime Vendor (PPV) Programs. The contract covers a base year and four one-year options, with one award made in the aggregate. Key requirements for offerors include providing prices for all line items and option years, including a 0.5% Cost Recovery Fee, and submitting unique 11-digit National Drug Codes (NDCs) for each product. Non-manufacturers must provide a Letter of Commitment from their manufacturer. The solicitation details product registration, backorder procedures (including potential buy-against agreements), packaging, barcoding (including DSCSA requirements), and adherence to cGMP standards. Contractors will be paid by PPVs, not directly by the government, and must have a Master Agreement and Pharmaceutical Pricing Agreement in place with the VA for covered drugs. Quarterly sales reports and Cost Recovery Fee payments are mandatory.
    Lifecycle
    Title
    Type
    6505--Allopurinol Tablets
    Currently viewing
    Solicitation
    6505--Allopurinol Tablets
    Presolicitation
    Similar Opportunities
    6505--Zonisamide Capsules
    Buyer not available
    The Department of Veterans Affairs (VA) intends to issue a Request for Proposal (RFP) for the unrestricted procurement of Zonisamide Capsules, which will serve various federal entities including the Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). The contract will be awarded to a single offeror capable of providing an uninterrupted supply of the specified medications, with a contract period of one year and four optional one-year extensions. The procurement is critical for ensuring the availability of these pharmaceutical products, which are essential for patient care within the VA and other federal health facilities. Interested parties should monitor SAM.gov for the solicitation, expected to be issued around December 15, 2025, with a closing date of December 30, 2025, and may direct inquiries to Chris Carthron at Christopher.Carthron@va.gov.
    760-25-1-050-0154 -Leavenworth CMOP THYROID TABLETS -(VA-25-00022614)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Armour Thyroid tablets for the Leavenworth Consolidated Mail Outpatient Pharmacy (CMOP) under solicitation number 36C77025Q0079. This Request for Quotation (RFQ) emphasizes the need for specific brand-name pharmaceuticals, with a focus on compliance with federal regulations, including the Drug Supply Chain Security Act and the Buy American Act. The procurement process aims to ensure a reliable supply of essential medications for veterans, with a firm-fixed-price contract expected to be awarded based on fair market evaluations. Interested vendors must submit their quotes by December 27, 2024, at 4:00 PM CST, and can direct inquiries to Jennifer L. Knight at jennifer.knight@va.gov or by phone at 913-684-0162.
    VISN 21 Lenalidomide Capsules Multiple Strengths (Generic)
    Buyer not available
    The Department of Veterans Affairs (VA) is conducting a Sources Sought notice to identify vendors capable of supplying Lenalidomide Capsules in multiple strengths, specifically for VISN 21, which includes locations in California, Hawaii, Nevada, and Manila, Philippines. The contractor must be a Certified Lenalidomide REMS Pharmacy, licensed in the applicable states, and comply with all relevant federal, state, and VA regulations, including USP <800> for hazardous drugs. This procurement is critical as Lenalidomide is an oral anti-cancer medication, and the contract will span five one-year ordering periods from March 1, 2026, to February 28, 2031, requiring timely and compliant delivery of FDA-approved products. Interested vendors should submit their capability statements and relevant information to David J. Alvarez at david.alvarez4@va.gov by 10:00 AM Pacific Time on December 10, 2025.
    Metaxalone Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in both 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal regulations and the submission of a subcontracting plan for large businesses. Metaxalone is a critical medication used for muscle relaxation, highlighting the importance of reliable supply for military personnel. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, at 3:00 PM EST, and can reach out to Jeremy Brown or Jason Wray for further inquiries.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Sertraline Tablets
    Buyer not available
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for the procurement of Sertraline Tablets in 25MG, 50MG, and 100MG dosages, with various bottle counts required over a base year and four option years. This solicitation, identified as SPE2D2-26-R-0002, emphasizes the importance of these pharmaceuticals in supporting military personnel's health and well-being. Interested contractors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 10, 2025, at 3:00 PM EST, and adhere to specific contractual obligations, including a subcontracting plan and compliance with various FAR and DFARS clauses. For further inquiries, potential bidders can contact Christopher Newman at christopher.newman@dla.mil or Jason Wray at jason.wray@dla.mil.
    Dimethyl Fumarate DR Presolicitation
    Buyer not available
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    6505--Biologics by McKesson Specialty Pharmacy (Lenalidomide) (VA-26-00016920)
    Buyer not available
    The Department of Veterans Affairs is seeking qualified suppliers to provide Lenalidomide, a pharmaceutical product, for the Oscar G. Johnson VA Medical Center located in Iron Mountain, MI. This procurement will be conducted through a Brand Name or Equal Request for Quotation (RFQ) under firm-fixed price terms, following FAR Part 13 Simplified Acquisition Procedures. Lenalidomide is crucial for treating certain conditions, making this procurement significant for patient care within the VA system. Interested offerors must submit an itemized quote along with sufficient technical documentation via email to arneil.genus@va.gov by 3 p.m. Central on December 1, 2025, as telephone inquiries will not be accepted.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Buyer not available
    The Department of Defense (DoD) is soliciting quotes for pharmaceutical agents as part of its Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) through the Defense Health Agency (DHA). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs to determine their classification within the formulary. The P&T Committee will review newly approved drugs, including agents for pulmonary, gynecological, endocrine, atopy, skeletal muscle relaxants, and pain management, with quotes due by December 9, 2025, ahead of the committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Stephanie Erpelding or Tracy Banks for further details and ensure compliance with submission requirements outlined in the RFQ HT9402-26-Q-9102.
    Q517--36C249-26-AP-0130 - VISN - Annual Wall-to-Wall Pharmacy Inventory
    Buyer not available
    The Department of Veterans Affairs, through the Network Contracting Office 9, is seeking proposals for Annual Wall-to-Wall Pharmacy Inventory services across various VA Medical Centers within VISN 09. The procurement aims to secure contractor support for the physical counting of both controlled and non-controlled pharmacy drugs, ensuring reconciliation with automated systems and compliance with VA, DEA, and FDA regulations. This service is critical for maintaining accurate inventory records and ensuring the proper management of pharmaceutical supplies within the VA healthcare system. Interested parties, particularly Service-Disabled Veteran-Owned Small Business Concerns (SDVOSBC), should note that the solicitation is anticipated to be issued on December 8, 2025, with responses due by December 15, 2025, and the contract award expected on December 17, 2025. For further inquiries, contact Mario Russell at mario.russell@va.gov.